P09.25 Identifying the correct patient (pt) population for ABT414: biomarker assays for epidermal growth factor receptor (EGFR) in pts with glioblastoma (GBM)

Aim: Aberrant EGFR signaling plays a vital role in GBM oncogenesis. ABT414 comprises an EGFR targeted antibody conjugated to the toxic agent monomethylauristatin F. An open label, 3 arm, phase I study (NCT01800695) is underway to evaluate 3 different ABT414 regimens in GBM. To understand the populat...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neuro Oncol
Prif Awduron: Lassman, A., Gan, H., Robert-Rapp, L., Ansell, P., Merrell, R., Kumthekar, P., Gomez, E., Holen, K., Reardon, D., van den Bent, M.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2017
Pynciau:
POSTER PRESENTATIONS
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5464164/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox036.281
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg